Alfuzosin for the management of benign prostate hyperplasia

David M. Weiner, Franklin C. Lowe

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Alfuzosin (UroXatral®, Sanofi-Synthelabo) a quinazoline derivative, has well-documented α1-adrenoreceptor antagonist activity. These receptors are present in the smooth muscle located at the bladder base, proximal urethra, prostate and prostatic capsule as well as in vascular and nervous systems. Consequently, alfuzosin has the ability to reduce the tone of these areas, effectively decreasing bladder outlet resistance. A sustained-release formulation of alfuzosin is currently available in Europe and is FDA-approved in the US. The confirmed efficacy, proven bioavailability and good cardiovascular safety profile support the use of this drug for the management of lower urinary tract symptoms secondary to benign prostate hyperplasia (BPH). These findings have been confirmed in a large cohort of patients treated in general practice. Additionally, treatment with alfuzosin has demonstrated a favourable impact on quality of life of patients with BPH.

Original languageEnglish (US)
Pages (from-to)2057-2063
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Volume4
Issue number11
DOIs
StatePublished - Nov 2003
Externally publishedYes

Fingerprint

Hyperplasia
Prostate
Urinary Bladder
Quinazolines
Lower Urinary Tract Symptoms
Urethra
General Practice
Nervous System
Biological Availability
Capsules
Smooth Muscle
Blood Vessels
Quality of Life
alfuzosin
Safety
Pharmaceutical Preparations
Therapeutics

Keywords

  • α-antagonist
  • Alfuzosin
  • Benign prostate hyperplasia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Alfuzosin for the management of benign prostate hyperplasia. / Weiner, David M.; Lowe, Franklin C.

In: Expert Opinion on Pharmacotherapy, Vol. 4, No. 11, 11.2003, p. 2057-2063.

Research output: Contribution to journalArticle

@article{8502ac7c20554d02a8778444f2edc694,
title = "Alfuzosin for the management of benign prostate hyperplasia",
abstract = "Alfuzosin (UroXatral{\circledR}, Sanofi-Synthelabo) a quinazoline derivative, has well-documented α1-adrenoreceptor antagonist activity. These receptors are present in the smooth muscle located at the bladder base, proximal urethra, prostate and prostatic capsule as well as in vascular and nervous systems. Consequently, alfuzosin has the ability to reduce the tone of these areas, effectively decreasing bladder outlet resistance. A sustained-release formulation of alfuzosin is currently available in Europe and is FDA-approved in the US. The confirmed efficacy, proven bioavailability and good cardiovascular safety profile support the use of this drug for the management of lower urinary tract symptoms secondary to benign prostate hyperplasia (BPH). These findings have been confirmed in a large cohort of patients treated in general practice. Additionally, treatment with alfuzosin has demonstrated a favourable impact on quality of life of patients with BPH.",
keywords = "α-antagonist, Alfuzosin, Benign prostate hyperplasia",
author = "Weiner, {David M.} and Lowe, {Franklin C.}",
year = "2003",
month = "11",
doi = "10.1517/14656566.4.11.2057",
language = "English (US)",
volume = "4",
pages = "2057--2063",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Alfuzosin for the management of benign prostate hyperplasia

AU - Weiner, David M.

AU - Lowe, Franklin C.

PY - 2003/11

Y1 - 2003/11

N2 - Alfuzosin (UroXatral®, Sanofi-Synthelabo) a quinazoline derivative, has well-documented α1-adrenoreceptor antagonist activity. These receptors are present in the smooth muscle located at the bladder base, proximal urethra, prostate and prostatic capsule as well as in vascular and nervous systems. Consequently, alfuzosin has the ability to reduce the tone of these areas, effectively decreasing bladder outlet resistance. A sustained-release formulation of alfuzosin is currently available in Europe and is FDA-approved in the US. The confirmed efficacy, proven bioavailability and good cardiovascular safety profile support the use of this drug for the management of lower urinary tract symptoms secondary to benign prostate hyperplasia (BPH). These findings have been confirmed in a large cohort of patients treated in general practice. Additionally, treatment with alfuzosin has demonstrated a favourable impact on quality of life of patients with BPH.

AB - Alfuzosin (UroXatral®, Sanofi-Synthelabo) a quinazoline derivative, has well-documented α1-adrenoreceptor antagonist activity. These receptors are present in the smooth muscle located at the bladder base, proximal urethra, prostate and prostatic capsule as well as in vascular and nervous systems. Consequently, alfuzosin has the ability to reduce the tone of these areas, effectively decreasing bladder outlet resistance. A sustained-release formulation of alfuzosin is currently available in Europe and is FDA-approved in the US. The confirmed efficacy, proven bioavailability and good cardiovascular safety profile support the use of this drug for the management of lower urinary tract symptoms secondary to benign prostate hyperplasia (BPH). These findings have been confirmed in a large cohort of patients treated in general practice. Additionally, treatment with alfuzosin has demonstrated a favourable impact on quality of life of patients with BPH.

KW - α-antagonist

KW - Alfuzosin

KW - Benign prostate hyperplasia

UR - http://www.scopus.com/inward/record.url?scp=0242407422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242407422&partnerID=8YFLogxK

U2 - 10.1517/14656566.4.11.2057

DO - 10.1517/14656566.4.11.2057

M3 - Article

VL - 4

SP - 2057

EP - 2063

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 11

ER -